INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2018

Homocysteine-lowering treatment with B vitamins was not associated with the risk of fracture in an updated meta-analysis of randomized trials.

Researchers conducted a secondary analysis of the AFPPS trial (1,021 participants randomized to 1 mg/day folic acid or placebo) alongside an updated meta-analysis of six RCTs (36,527 participants) evaluating homocysteine-lowering B-vitamin treatment on fracture risk. In the AFPPS, folic acid was not significantly associated with any fracture (RR = 0.95; 95% CI 0.61-1.48) or hip fracture (RR = 0.98; 95% CI 0.25-3.89). In the meta-analysis, interventions with folic acid and/or vitamin B12 yielded a pooled RR of 0.97 (95% CI 0.87-1.09) for any fracture and 1.00 (95% CI 0.81-1.23) for hip fracture. The authors concluded that no association was found between homocysteine-lowering treatment with B vitamins and fracture risk.

Study type
Secondary RCT analysis and meta-analysis of RCTs
Who was studied
1,021 trial participants (AFPPS) and 36,527 participants across 6 RCTs in the meta-analysis
What was measured
Risk of fractures of any type and hip fracture

THE PAPER

Homocysteine-Lowering Treatment and the Risk of Fracture: Secondary Analysis of a Randomized Controlled Trial and an Updated Meta-Analysis.

Garcia Lopez M, Baron JA, Omsland TK, Søgaard AJ, Meyer HE. JBMR Plus, 2018.

PubMed 30283911 ↗DOI 10.1002/jbm4.10045 ↗

Nutrients & adequacyBones & muscles

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.